Mark Jeffrey Delong holds the role of Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc. (APLS). Delong has reported 6 insider filings with the SEC since 2026. The most recent filing was in May 2026.
Every role Mark Jeffrey Delong has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Apellis Pharmaceuticals, Inc. (APLS)6 filingsUpdated Aug 30, 2026
Mark Jeffrey Delong is Chief Business & Strat Officer of Apellis Pharmaceuticals, Inc. (APLS). 6 SEC Form 4 filings on record, most recently on 14 May 2026. Most recent open-market trade: sold $8K of APLS on 13 February 2026. Lifetime open-market sales: $147K.
Every recent SEC Form 4 transaction Mark Jeffrey Delong has reported, most recent first.
InsiderAlpha's records for Mark Jeffrey Delong go back to 2026: 6 primary Form 4 filings, an average of 6.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who reported open-market trades in the last 12 months at the companies Mark Jeffrey Delong files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Mark Jeffrey Delong is a corporate insider, tracked as Chief Business & Strat Officer of Apellis Pharmaceuticals, Inc. (APLS). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 14 May 2026, one of 6 filings going back to 2026.
Recorded transactions: 0 open-market purchases and 4 open-market sales ($147K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$APLS Apellis Pharmaceuticals, Inc.4.9K shares @ --